Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marcello Salvaggio"'
Autor:
Filippo Albani, Lilia Sepe, Federica Fusina, Chiara Prezioso, Manuela Baronio, Federica Caminiti, Antonella Di Maio, Barbara Faggian, Maria Elena Franceschetti, Marco Massari, Marcello Salvaggio, Giuseppe Natalini
Publikováno v:
EClinicalMedicine, Vol 27, Iss , Pp 100562- (2020)
Background: Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection is associated with hypercoagulability caused by direct invasion of endothelial cells and/or proinflammatory cytokine release. Thromboprophylaxis with enoxaparin is rec
Externí odkaz:
https://doaj.org/article/ee09a7c36c1a48fc94c3117d8ed07263
Autor:
Laura Agnoletti, Maurizio Salvaggio, Rasula Beschi, Marcello Salvaggio, Emanuela Ferrari, Federica Fusina, Emanuela Facchi, Alberto C.S. Costa, Filippo Albani, Giuseppe Natalini
Publikováno v:
Salvaggio, M, Fusina, F, Albani, F, Salvaggio, M, Beschi, R, Ferrari, E, Costa, A, Agnoletti, L, Facchi, E & Natalini, G 2021, ' Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2 ', Journal of Clinical Medicine, vol. 10, no. 18 . https://doi.org/10.3390/jcm10184204
Journal of Clinical Medicine, Vol 10, Iss 4204, p 4204 (2021)
Journal of Clinical Medicine, 10(18)
Journal of Clinical Medicine
Volume 10
Issue 18
Journal of Clinical Medicine, Vol 10, Iss 4204, p 4204 (2021)
Journal of Clinical Medicine, 10(18)
Journal of Clinical Medicine
Volume 10
Issue 18
The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested
therefore, two doses may be administered
therefore, two doses may be administered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dba5b1703bb8e034a74e5a845e03ed9
https://doi.org/10.3390/jcm10184204
https://doi.org/10.3390/jcm10184204
Autor:
Federica Caminiti, Marcello Salvaggio, Federica Fusina, Marco Massari, Filippo Albani, Giuseppe Natalini, Manuela Baronio, M. E. Franceschetti, Barbara Faggian, Chiara Prezioso, Antonella Di Maio, Lilia Sepe
Publikováno v:
EClinicalMedicine
Albani, F, Sepe, L, Fusina, F, Prezioso, C, Baronio, M, Caminiti, F, Di Maio, A, Faggian, B, Franceschetti, M E, Massari, M, Salvaggio, M & Natalini, G 2020, ' Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study ', EClinicalMedicine, vol. 27, pp. 100562 . https://doi.org/10.1016/j.eclinm.2020.100562
EClinicalMedicine, Vol 27, Iss, Pp 100562-(2020)
EClinicalMedicine, 27. Lancet Publishing Group
Albani, F, Sepe, L, Fusina, F, Prezioso, C, Baronio, M, Caminiti, F, Di Maio, A, Faggian, B, Franceschetti, M E, Massari, M, Salvaggio, M & Natalini, G 2020, ' Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study ', EClinicalMedicine, vol. 27, pp. 100562 . https://doi.org/10.1016/j.eclinm.2020.100562
EClinicalMedicine, Vol 27, Iss, Pp 100562-(2020)
EClinicalMedicine, 27. Lancet Publishing Group
BACKGROUND: Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection is associated with hypercoagulability caused by direct invasion of endothelial cells and\or proinflammatory cytokine release. Thromboprophylaxis with enoxaparin is rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::033cba77a7c47c2a40771de6463cf3a5
https://pubmed.ncbi.nlm.nih.gov/33043287
https://pubmed.ncbi.nlm.nih.gov/33043287